Poland· PL-100379255
Roxiper
A rosuvastatin, perindopril und indapamid product containing rosuvastatinum + tert-butylamini perindoprilum + indapamidum, registered in Poland by Krka, d.d., Novo mesto. The same ATC class is registered in 3 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Rosuvastatin, perindopril und indapamid is registered in 3 of 19 countries.
Countries holding a registration under ATC C10BX13 (rosuvastatin, perindopril und indapamid), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Rosuvastatin, perindopril und indapamid · ATC C10BX13
3 / 19 countries
- Czechiaprice
- Finlandprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Rosuvastatinum + tert-Butylamini perindoprilum + Indapamidum
- Manufacturer
- Krka, d.d., Novo mesto
- Country
- Poland (PL)
- ATC code
- C10BX13
- ATC class
- Rosuvastatin, Perindopril und Indapamid
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 6
- gtin05909991390778
- gtin05909991390723
- gtin05909991390730
- gtin05909991390747
- gtin05909991390754
- gtin05909991390761
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under C10BX13
Rosuvastatin, perindopril und indapamid, as other registers publish it.
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
- CzechiaPEMIROSKrka, d.d., Novo mesto, Novo mesto
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ecd7e486-a21e-4577-b84a-f8f5dc75ef73 GET /v1/drugs/ecd7e486-a21e-4577-b84a-f8f5dc75ef73?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "20 mg + 4 mg + 1,25 mg",
"packaging": "05909991390723 ¦ Rp ¦ 130690\n10 tabl.\n05909991390730 ¦ Rp ¦ 130691\n20 tabl.\n05909991390747 ¦ Rp ¦ 130692\n30 tabl.\n05909991390754 ¦ Rp ¦ 130693\n60 tabl.\n05909991390761 ¦ Rp ¦ 130694\n90 tabl.\n05909991390778 ¦ Rp ¦ 130695\n100 tabl.",
"substance": "Rosuvastatinum 20 mg + tert-Butylamini perindoprilum 4 mg + Indapamidum 1.25 mg",
"common_name": "Rosuvastatinum + tert-Butylamini perindoprilum + Indapamidum",
"pl_product_id": "100379255",
"pozwolenie_nr": "25064",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about rosuvastatin, perindopril und indapamid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.